SCHEMBL20907159

SCHEMBL20907159

COC(=O)c1cnc(OCCS(C)(C)C)cc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.42
GAA P10253 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.39
CFTR P13569 4/20 0.39
GABRA5 P31644 2/20 0.39
LMNA P02545 1/20 0.35
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20906973 0.87 GABRA5 (0.49) MAPTKDM4EPOLBGAANPSR1
SCHEMBL20796701 0.84 MAPT (0.55) MAPTKDM4EPOLBGAANPSR1
SCHEMBL3780170 0.81 MAPT (0.63) MAPTKDM4EPOLBGAANPSR1
SCHEMBL20907244 0.80 MAPT (0.34) MAPTMEN1KMT2A
SCHEMBL20907179 0.79 ALDH1A1 (0.33) MAPTPOLBALDH1A1MEN1KMT2A
SCHEMBL12302078 0.75 MAPT (0.55) MAPTKDM4ENPC1ALDH1A1MAPK1
SCHEMBL473983 0.73 MAPT (0.60) MAPTKDM4EPOLBGAANPSR1
SCHEMBL15038347 0.73 MAPT (0.60) MAPTKDM4EGAANPC1ALDH1A1
SCHEMBL1819192 0.73 MAPT (0.53) MAPTKDM4EPOLBNPC1ALDH1A1
SCHEMBL4151636 0.70 MAPT (0.51) MAPTKDM4EGAANPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING FACIT INC. (CA) 2023-07-13 US disclosed
US-11319299-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2022-05-03 US disclosed
US-11174250-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2021-11-16 US disclosed
US-20200385371-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2020-12-10 US disclosed
US-20190119264-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2019-04-25 US disclosed
US-20190112290-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2019-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319299-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 MAPT 2234/4885KDM4E 217/4885POLB 3553/4885
US-11174250-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 MAPT 2102/4885KDM4E 231/4885POLB 3493/4885
US-20200385371-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 MAPT 1412/4885KDM4E 967/4885POLB 3119/4885
US-20190119264-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 MAPT 1412/4885KDM4E 967/4885POLB 3119/4885
US-20190112290-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 MAPT 1664/4885KDM4E 672/4885POLB 3118/4885
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 MAPT 2234/4885KDM4E 217/4885POLB 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.